The new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is expected to launch in the second half of 2026 ...
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings...
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,...
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system...
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress,...
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable...
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring...
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable...
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,...